CFTR

Chr 7

CF transmembrane conductance regulator

Epithelial ion channel that plays an important role in the regulation of epithelial ion and water transport and fluid homeostasis (PubMed:26823428). Mediates the transport of chloride ions across the cell membrane (PubMed:10792060, PubMed:11524016, PubMed:11707463, PubMed:12519745, PubMed:12529365, PubMed:12588899, PubMed:12727866, PubMed:15010471, PubMed:17036051, PubMed:1712898, PubMed:17182731, PubMed:19398555, PubMed:19621064, PubMed:22178883, PubMed:25330774, PubMed:26846474, PubMed:28087700, PubMed:8910473, PubMed:9804160). Possesses an intrinsic ATPase activity and utilizes ATP to gate its channel; the passive flow of anions through the channel is gated by cycles of ATP binding and hydrolysis by the ATP-binding domains (PubMed:11524016, PubMed:15284228, PubMed:26627831, PubMed:8910473). The ion channel is also permeable to HCO(3)(-); selectivity depends on the extracellular chloride concentration (PubMed:15010471, PubMed:19019741). In vitro, mediates ATP-dependent glutathione flux (PubMed:12727866). Exerts its function also by modulating the activity of other ion channels and transporters (PubMed:12403779, PubMed:22121115, PubMed:22178883, PubMed:27941075). Plays an important role in airway fluid homeostasis (PubMed:16645176, PubMed:19621064, PubMed:26823428). Contributes to the regulation of the pH and the ion content of the airway surface fluid layer and thereby plays an important role in defense against pathogens (PubMed:14668433, PubMed:16645176, PubMed:26823428). Modulates the activity of the epithelial sodium channel (ENaC) complex, in part by regulating the cell surface expression of the ENaC complex (PubMed:17182731, PubMed:17434346, PubMed:27941075). Inhibits the activity of the ENaC channel containing subunits SCNN1A, SCNN1B and SCNN1G (PubMed:17182731). Inhibits the activity of the ENaC channel containing subunits SCNN1D, SCNN1B and SCNN1G, but not of the ENaC channel containing subunits SCNN1A, SCNN1B and SCNN1G (PubMed:17182731, PubMed:27941075). May regulate bicarbonate secretion and salvage in epithelial cells by regulating the transporter SLC4A7 (PubMed:12403779). Can inhibit the chloride channel activity of ANO1 (PubMed:22178883). Plays a role in the chloride and bicarbonate homeostasis during sperm epididymal maturation and capacitation (PubMed:19923167, PubMed:27714810, PubMed:29393851)

ResearchGenerating clinical summary…

Primary Disease Associations & Inheritance

UniProtCystic fibrosis
UniProtCongenital bilateral absence of the vas deferens

Clinical highlights

Gene-disease validity (ClinGen)
cystic fibrosis · ARDefinitivesufficient evidence for diagnostic panels
12
Active trials
1302
Pubs (1 yr)
P/LP submissions
P/LP missense
1.31
LOEUF
Multiple*
Mechanism· predicted
Some data sources returned errors (2)

ncbi: Error: NCBI fetch failed: 429 https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi

omim: Error: OMIM fetch failed: 429

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
1.31LOEUF
pLI 0.000
Z-score -0.73
OE 1.09 (0.911.31)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?
-3.14Z-score
OE missense 1.32 (1.251.39)
996 obs / 753.5 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios?
LoF OE?1.09 (0.911.31)
00.351.4
Missense OE?1.32 (1.251.39)
00.61.4
Synonymous OE?0.94
01.21.6
LoF obs/exp: 84 / 77.0Missense obs/exp: 996 / 753.5Syn Z: 0.77

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

CFTR · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Cystic Fibrosis

Testing Drug Efficacy in Cystic Fibrosis Through N-of-1 Trials

RECRUITING
NCT04580368Phase NAChildren's Hospital Medical Center, CincinnatiStarted 2021-05-01
CFTR Modulators
Cystic Fibrosis

Impact of a Coordinated Dietetic-adapted Physical Activity Program on the Percentage of Lean Body Mass in Adults With Cystic Fibrosis Treated With Elexacaftor-Tezacaftor-Ivacaftor: Multicentre Randomised Controlled Trial

RECRUITING
NCT06457451Phase NAUniversity Hospital, ToursStarted 2024-11-25
DIAPASOM program
Cystic Fibrosis

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

ACTIVE NOT RECRUITING
NCT05331183Phase PHASE3Vertex Pharmaceuticals IncorporatedStarted 2022-11-23
ELX/TEZ/IVAIVA
Cystic Fibrosis-related DiabetesCystic Fibrosis

Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function

RECRUITING
NCT04530383Phase PHASE2University of Kansas Medical CenterStarted 2022-02-14
Metformin Hydrochloride
Cystic FibrosisLiver Disease

Genetic Modifiers of Cystic Fibrosis (CF) Liver Disease

ACTIVE NOT RECRUITING
NCT00804583University of North Carolina, Chapel HillStarted 2004-03
Cystic Fibrosis Lung

4D-710 in Adult Patients With Cystic Fibrosis

RECRUITING
NCT05248230Phase PHASE24D Molecular TherapeuticsStarted 2022-03-29
4D-710
Cystic FibrosisCFTR Gene Mutation

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

RECRUITING
NCT06747858Phase PHASE2Arcturus Therapeutics, Inc.Started 2024-12-12
ARCT-032
Cystic Fibrosis (CF)CFTR Gene Mutation

Cystic Fibrosis in the Kidney: Monitoring the Effectiveness of Elexacaftor/tezacaftor/ivacaftor in Urine After a Short Pause of Therapy

RECRUITING
NCT05818319Phase NAUniversity of AarhusStarted 2023-06-01
12 hours ETI pause36 hours ETI pause60 hours ETI pause
Chronic PancreatitisGenetic MutationSmoking, Tobacco

An Observational Study on the Natural Course of Chronic Pancreatitis

ACTIVE NOT RECRUITING
NCT04574297Changhai HospitalStarted 2011-01-01
smoking and alcohol assumptiongenetic sequencing
Cystic Fibrosis

Physical Activity Profile and Sedentary Behaviour in Adults With Cystic Fibrosis

RECRUITING
NCT06507956Hospices Civils de LyonStarted 2024-09-17
Characterize the physical activity and sedentary lifestyle profile of adults with cystic fibrosis
Cystic Fibrosis

A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)

RECRUITING
NCT06526923Phase PHASE1, PHASE2Spirovant Sciences, Inc.Started 2024-09-16
SP-101 and doxorubicin Cohort 1SP-101 and doxorubicin Cohort 2
Cystic Fibrosis (CF)

Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.

RECRUITING
NCT07363304Meyer Children's Hospital IRCCSStarted 2025-12-02
Elexacaftor, Tezacaftor, Ivacaftor